Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
boston blog main
boston top stories
5
×
life sciences
national blog main
boston
clinical trials
drugs
alnylam pharmaceuticals
aminolevulinic acid
deals
fda
givosiran
national top stories
new york blog main
new york top stories
rna interference
roche
san francisco blog main
san francisco top stories
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
biontech
biopharma
biotech
blueprint medicines
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
cancer
companion diagnostic
curevac
detroit blog main
detroit top stories
dna sequencing
duchenne
eli lilly
entrectinib
europe blog main
What
second
5
×
medicine
rna
drug
fda
new
alnylam
approval
cancer
deal
interference
pharmaceuticals
rnai
seek
speedy
time
ago
approved
bets
betting
billion
bio
biopharma
cleared
comes
companies
cut
data
date
deeper
dna
duchenne
effective
enticed
evidence
far
fingerprint
gene
genetic
going
Language
unset
Current search:
second
×
photo
×
" boston top stories "
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines